Pfizer Overseas Pharmaceuticals & Ors v Eli Lilly & Co & Ors

Link copied
Case Copied 26 min read

[2006] HCATrans 271

IN THE HIGH COURT OF AUSTRALIA

Office of the Registry
  Melbourne  No M150 of 2005

B e t w e e n -

PFIZER OVERSEAS PHARMACEUTICALS

First Applicant

PFIZER AUSTRALIA PTY LTD

Second Applicant

C P PHARMACEUTICALS INTERNATIONAL CV

Third Applicant

PFIZER MANUFACTURING LLC

Fourth Applicant

PFIZER PRODUCTION LLC

Fifth Applicant

and

ELI LILLY & COMPANY

First Respondent

ELI LILLY AUSTRALIA PTY LTD

Second Respondent

ELI LILLY & COMPANY LTD

Third Respondent

Application for special leave to appeal

GLEESON CJ
HAYNE J

TRANSCRIPT OF PROCEEDINGS

AT MELBOURNE ON FRIDAY, 2 JUNE 2006, AT 11.31 AM

Copyright in the High Court of Australia

__________________

MR D. SHAVIN, QC:   May it please the Court, I appear for the applicant with my learned friend, MS H.M.J. ROFE.  (instructed by Corrs Chambers Westgarth)

MR D.K. CATTERNS, QC:   May it please the Court, I appear with my learned friend, MS K.J. HOWARD, for the respondents.  (instructed by Blake Dawson Waldron)

GLEESON CJ:   Yes, Mr Shavin.

MR SHAVIN: If the Court pleases. The case raises for consideration the issue of the meaning of the words “matter described in the specification” in section 40(3) of the Patents Act 1990 in a way that has not previously been considered by this Court. The question which sharply divided the Federal Court below was what constituted a fair basis for a claim where the specification contained what Justice Crennan described at paragraph 422 of her judgment as a broad disclosure and a narrow disclosure and there are claims as to both.

GLEESON CJ:   I had an impression, correct me if am wrong, that the question that divided the majority and the minority in the Federal Court was a question of construction of the specification.

MR SHAVIN:   In our respectful submission, no, your Honour, for this reason.  The patent discloses a method of treatment for erectile dysfunction.  The patent commences its discussion by saying it relates to a very wide class of compounds and there is disclosed a new use for a class of compounds, compounds that were previously disclosed in the Bell patent referred to on page 7 of the specification.  There is also disclosed within the specification the pharmacological action which mediates the treatment and that pharmacological action explains not only why that class of compounds can be used as a method of treatment, but also discloses how you engage in the treatment and that is said so expressly at the foot of page 9 to the top of page 10 of the specification. 

The majority, in approaching the specification, looked only to the class of compounds.  They looked only to words which they sought to attribute a description of the invention.  In a sense they looked to words akin to a consistory clause and said that is all to which we will look.  They did not look or consider in the context of fair basis the broader disclosure.  They averted the process, whereas this Court affirmed the statement of Justice Gummow…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Overseas Pharmaceuticals & Ors v Eli Lilly & Co & Ors and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2006] HCATrans 271
Decision Date

CaseChat Overview and Summary

In the High Court of Australia, Pfizer Overseas Pharmaceuticals and others (the appellants) appealed against a decision of the Full Federal Court concerning the validity of certain patent claims held by Eli Lilly and Company and others (the respondents). The dispute centred on the respondents' patent for a pharmaceutical compound known as duloxetine, which is the active ingredient in the antidepressant medication Cymbalta. The appellants sought to market generic versions of duloxetine, alleging that the respondents' patent was invalid.

The primary legal issue before the High Court was whether the respondents' patent claims, specifically claims 1 and 2, were valid and infringed by the appellants. This involved a determination of whether the patent sufficiently disclosed the invention, particularly in relation to the compound's therapeutic use, and whether the claims were novel and involved an inventive step. The appellants contended that the patent lacked sufficient disclosure and that the claimed invention was obvious in light of prior art.

The High Court, in a joint judgment delivered by Gleeson CJ and Hayne J, found that the patent claims were valid. Their Honours reasoned that the patent specification adequately disclosed the invention, including the therapeutic use of duloxetine, by providing sufficient information to enable a skilled person to identify and use the compound for its intended purpose. The Court applied the principles of patent law concerning sufficiency of disclosure, novelty, and inventive step, finding that the respondents had met the requirements of the Patents Act 1990 (Cth). The appeal was accordingly dismissed.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established